Emergent BioSolutions Reports Financial Results for Second Quarter and First ... Wall Street Journal (press release) ... otlertuzumab and rituximab in relapsed CLL patients; -- Announced positive preclinical efficacy and pharmacokinetic data for ES414, a bispecific ADAPTIR(TM) (Modular Protein Technology) molecule in development for castration-resistant prostate ... |
